BriaCell Closes First Tranche of Previously Announced Non-Brokered Private Placement

BERKELEY, Calif., and VANCOUVER, British Columbia, March 25, 2019 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that it has closed the first tranche (“First Tranche”) of its previously-announced (March 20, 2019) non-brokered private placement of up to 20,000,000 common shares of the Company at a price of C$0.10 per common share for gross proceeds of up to approximately C$2,000,000 (the “Offering”). A total of 7,500,000 common shares at a price of C$0.10 per common share have been issued under the First Tranche for gross proceeds of C$750,000. The Company paid a total of C$15,000 cash finder’s fees on subscriptions under the First Tranche.

The Company intends to use the net proceeds from the Offering: (i) to finance the Company’s Phase IIa combination study of Bria-IMT™ with KEYTRUDA® by Merck & Co. Inc. (NYSE: MRK) in advanced breast cancer; (ii) to finance the Company’s pursuit of other research opportunities; and (iii) for working capital and general corporate purposes.

The closing of the second and final tranche of the Offering is scheduled to occur on or about March 28, 2019. All securities issued under the Offering will be subject to a hold period expiring four months plus one day following the closing of the Offering. The Offering remains subject to final approval from the TSX Venture Exchange.

The securities have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About BriaCell

BriaCell is an immuno-oncology focused biotechnology company developing targeted and safe approaches for the management of cancer.

BriaCell is currently conducting a Phase I/IIa clinical trial of Bria-IMT™, its lead candidate, in a combination study with pembrolizumab KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK). The combination study is listed in as NCT03328026.

BriaCell is developing Bria-OTS™, an off-the-shelf personalized immunotherapy, for advanced breast cancer. Bria-OTS™ immunotherapy treatments are personalized to match the patient without the need for personalized manufacturing. Bria-OTS™, which is expected to cover over 90% of the patient population, is designed to produce a potent and selective immune response against the cancer of each patient while eliminating the time, expense and complex manufacturing logistics associated with other personalized immunotherapies.

For additional information on BriaCell, please visit:

Cautionary Note Regarding Forward-Looking Information

Except for the statements of historical fact, this news release contains “forward-looking information” within the meaning of the applicable Canadian securities legislation which involves known and unknown risks relevant to the Company in particular and to the biotechnology and pharmaceutical industries in general, uncertainties and other factors that may cause actual events to differ materially from current expectation. These risks are more fully described in the Company’s public filings available at

Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

For further information, please contact:
BriaCell Therapeutics Corp.:
Farrah Dean
Manager, Corporate Development
Email: [email protected]
Phone: 1-888-485-6340

Skip to content